C6-17 / AFFiRiS - LARVOL DELTA

Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease. (PubMed, Neurobiol Dis) - "Compared to CTRL mAB or vehicle treated mice, the mAB C6-17 treated YAC128 animals showed improved body weight and motor behaviors, a delayed progression in motor deficits and reduced striatal EM48 immunoreactivity. These results provide the first proof of concept for the feasibility and therapeutic efficacy of an antibody-based anti-HTT passive immunization approach and suggest this modality as a potential new HD treatment strategy."

IO biomarker • Journal • Preclinical • Genetic Disorders • Huntington's Disease • Movement Disorders • CASP6

AC Immune acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases (GlobeNewswire) - "AFFiRiS...announced that AC Immune SA...is acquiring AFFiRiS’ anti-alpha-synuclein programs targeting neurodegenerative diseases caused by misfolded forms of human self-proteins. All acquired programs are based on AFFiRiS´ AFFITOME® technology....The all-stock acquisition is valued at USD 58.7 million. Under the terms of the agreement, AC Immune is acquiring all of AFFiRiS´ assets and underlying intellectual property related to active vaccine candidates targeting alpha-synuclein and USD 5 million in cash for 7.1 million shares of AC Immune common stock based on a price of USD 8.26 per common share....The acquisition is subject to customary regulatory approval in Austria and expected to complete at the beginning of Q4 2021."

M&A • CNS Disorders • Parkinson's Disease